SIGN UP
LOG IN
MARKET
INO
INO
Inovio Pharmaceu
NASDAQ
0.3942
+0.0159
+4.20%
Pre Market: 0.3908 -0.0034 -0.86% 09:16 12/01 EST
OPEN
0.3783
PREV CLOSE
0.3783
HIGH
0.3950
LOW
0.3712
VOLUME
26.42K
TURNOVER
0
52 WEEK HIGH
2.050
52 WEEK LOW
0.3240
MARKET CAP
107.61M
P/E (TTM)
-0.6205
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at INO last week (1120-1124)?
Weekly Report · 5d ago
Weekly Report: what happened at INO last week (1113-1117)?
Weekly Report · 11/20 09:30
Weekly Report: what happened at INO last week (1106-1110)?
Weekly Report · 11/13 09:28
Analysts Offer Insights on Healthcare Companies: Vertex (VERX), Inovio Pharmaceuticals (INO) and Pliant Therapeutics (PLRX)
TipRanks · 11/10 12:30
Inovio Pharmaceu: Quarterly report
Press release · 11/10 08:16
Inovio Pharmaceu: Current report
Press release · 11/10 08:16
Inovio files for $300M mixed shelf
Inovio pharmaceuticals files for $300m mixed shelf offering. Inovio pharmaceutics filed a prospectus to offer and sell common stock, preferred stock, debt securities, and warrants to raise $300 million. The prospectus is not an offer to sell the securities.
Seeking Alpha · 11/09 23:15
Inovio Pharmaceuticals Q3 EPS $(0.13), Inline, Sales $388.45K Beat $120.00K Estimate
Inovio pharmaceuticals reported quarterly losses of $0.13 per share. The company reported quarterly sales of $388.45 thousand. Inovio's quarterly sales beat the analyst consensus estimate of $120.00 thousand by 223.71 percent. The company reported a 13.33 percent increase in quarterly losses.
Benzinga · 11/09 22:17
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. The Company’s lead candidates are focused on diseases associated with HPV. Its DNA medicines pipeline includes INO-3107 for HPV-related Recurrent Respiratory Papillomatosis (RRP), VGX-3100 for the treatment of HPV-related Cervical HSIL, INO-5401 for the treatment of Glioblastoma Multiforme (GBM), INO-5151 (INO-5150 + INO-9012) for the treatment of Prostate Cancer, INO-4800 for COVID-19, INO-4201 for Ebola Virus Disease, INO-4700 for Middle East Respiratory Syndrome (MERS) and INO-4500 for Lassa Fever. Its DNA medicine platform consists of DNA plasmids and its investigational smart device, CELLECTRA, which is used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of three models.
Webull offers Inovio Pharmaceuticals Inc stock information, including NASDAQ: INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading INO stock methods without spending real money on the virtual paper trading platform.